Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
评估选择性白三烯B4生物合成抑制剂Acebilustat治疗轻中度2019冠状病毒病门诊患者的疗效:一项随机、双盲、安慰剂对照的II期试验
期刊:Clinical Infectious Diseases
影响因子:7.3
doi:10.1093/cid/ciad187
Levitt, Joseph E; Hedlin, Haley; Duong, Sophie; Lu, Di; Lee, Justin; Bunning, Bryan; Elkarra, Nadia; Pinsky, Benjamin A; Heffernan, Eileen; Springman, Eric; Moss, Richard B; Bonilla, Hector F; Parsonnet, Julie; Zamanian, Roham T; Langguth, Jamison J; Bollyky, Jenna; Khosla, Chaitan; Nicolls, Mark R; Desai, Manisha; Rogers, Angela J